Walter Greenblatt & Associates | Bridging the Gap Between Science & Investment

from INCEPTION to EXIT

INCEPTION

WALTER GREENBLATT & ASSOC.
helps scientists raise the captial they need to create proof-of-concepts

DEVELOPMENT

WALTER GREENBLATT & ASSOC.
helps scientists bring their product to the market

GROWTH

WALTER GREENBLATT & ASSOC.
helps raise capital necessary for company to reach the next stage of development

EXIT

WALTER GREENBLATT & ASSOC.
helps biotech owners plan exit strategies that yield “Maximum Value”

November 2013
Callidus Biopharma acquired by Amicus Therapeutics (NASDAQ-FOLD) for $15 million upfront payment with potential milestone payments totaling $115 million.

Click here to read the full press release...
March 2013
Callidus BioPharma Announces Close of $4.6 million from Strategic Investors & Angels.


Read the full press release... January 2012
Callidus Biopharma receives $1.6 million from Angel and strategic investors.
August 2011
Lerner Medical Devices receives $1.0 million from Angel investors.

2009-10
Lerner Medical receives $4.5 million from Angel investors.

Dec. 2007
Lerner Medical receives $3.3 million from Angel investors.
March 2011
Core Essence Orthopaedics receives $5.2 million Series B from institutional VC investors.

October 2010
Core Essence Orthopaedics receives a $2.9 million Series A from Angel investors.
November 2013
Hygeia Therapeutics acquired by Stratus Media Group (OTCBB-SMDI).
Read the full press release... March 2010
Hygeia Therapeutics receives $2.0 million from Angel Investors.
June 2008
MedAvante receives $20 million from institutional VC investors.

Sept. 2007
MedAvante receives $6.7 million from Angel investors.
July 2011
Shire Pharmaceuticals purchases Advanced BioHealing for $750 million in cash.
November 2009
Lerner Medical Devices receives 510(k) clearance from the FDA for Levia®.
June 2008
MedAvante closes on $20 million Institutional round led by Goldman Sachs and Trevi Health Ventures; Walter Greenblatt & Associates, exclusive financial advisor to MedAvante.
August 2007
WuXi PharmaTech (NYSE: WX), IPOs on the New York Stock Exchange with a $1 billion market cap.
More